
Medicine treats the evaluation of emerging technologies as a technical problem, but it is not. It is fundamentally an economic problem.
When does a ₹30,000 genetic test represent excellent value and when does it represent wasted money? The answer depends on a question members of the medical profession almost never discuss: who’s paying?

Leave a Reply